Latest News From Pharmachem

    January

  • Boosting vitamin D could slow progression, reduce severity of multiple sclerosis

    21 January, 2014

    For patients in the early stages of multiple sclerosis (MS), low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a new study led by Harvard School of Public Health (HSPH) investigators in collaboration with Bayer HealthCare. The findings suggest that patients in the early stages of MS could stave off disease symptoms by increasing their vitamin D intake.

    Continue Reading »

  • Pharmachem News

    22 January, 2014

    Great News for the network in 2013 exceeding almost all targets. We successfully achieved funding for 2014, training requests are now being taken, please feel free to contact us with your training requirements for 2014 susancostello@pharmachemskillnet.ie

    Continue Reading »

  • Accredited GXP programme 2014

    22 January, 2014

    Accredited GXP programme to run in 2014

    Continue Reading »

  • 7 Habits of Highly Effective People

    22 January, 2014

    After the success of 7 habits workshop in 2013, there will be a programme running in Cork in June

    Continue Reading »

  • Career Zoo Saturday, 15 February 2014, at 10am -5pm

    22 January, 2014

    The Convention Centre Dublin. Get ready for Ireland's biggest and most exciting career event for professionals and graduates looking to advance their careers. Don't miss Career Zoo this February if you'd like to:

    Continue Reading »

  • JOBS EXPO 2014

    31 January, 2014

    In association with DoneDealJobs Our next Jobs Expo events are now well within sight. http://jobsexpo.ie/

    Continue Reading »

  • February

  • Boston Scientific reports better-than-expected quarterly earnings

    05 February, 2014

    Medical device maker, which employs more than 4,500 people in Ireland, earned $108m

    Continue Reading »

  • Pfizer and Merck to collaborate on innovative anti-cancer combination studies

    Pfizer and Merck to collaborate on innovative anti-cancer combination studies

    07 February, 2014

    Pfizer Inc. (NYSE:PFE) has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. A Phase I/II clinical study will evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer's axitinib (INLYTA®) in renal cell carcinoma (RCC). A separate Phase I study will evaluate the safety and tolerability of the combination of MK-3475 and PF-05082566 (PF-2566), Pfizer's investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell proliferation and survival. "There has been notable progress in the cancer immunotherapy field over the last year, with new clinical data showing promising efficacy and tolerability for emerging therapies - particularly those that target the PD-1 pathway," said Dr. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology. "These investigational therapies, which harness the body's immune system to treat disease, may hold the greatest potential for patients with cancer when used in combination with other immuno-oncology agents, like PF-2566, to amplify anti-tumor immune responses, or with targeted agents, like axitinib, to optimize their effectiveness. We are pleased to collaborate with Merck to study a diverse group of our anti-cancer agents in combination with MK-3475, with the goal of identifying more efficacious treatment options for patients."

    Continue Reading »

  • Novartis expands cancer immunotherapy research program with acquisition of CoStim

    17 February, 2014

    Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

    Continue Reading »

  • March

  • Cancer vaccine could use immune system to fight tumors

    04 March, 2014

    Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer. These findings, published in the Feb. 27 online edition of the journal Gene Therapy, build on previously reported research and could lead to new treatments for cancer.

    Continue Reading »

  • Major breakthrough in developing new cancer drugs: Capturing leukemic stem cells

    19 March, 2014

    The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs

    Continue Reading »

  • New technique brings us closer to HIV and hepatitis C vaccines

    26 March, 2014

    Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research. Professor Eric Gowans from the University's Discipline of Surgery, based at the Basil Hetzel Institute at the Queen Elizabeth Hospital, has submitted a patent application for what he describes as a relatively simple but effective technique to stimulate the body's immune system response, thereby helping to deliver the vaccine. Read more... Shifting evolution into reverse promises cheaper, greener way to make new drugs TUESDAY, 25 MARCH 2014 This alternative approach to creating artificial organic molecules, called bioretrosynthesis, was first proposed four years ago by Brian Bachmann, associate professor of chemistry at Vanderbilt University. Now Bachmann and a team of collaborators report that they have succeeded in using the method to produce the HIV drug didanosine. The proof of concept experiment is described in a paper published online March 23 by the journal Nature Chemical Biology. Read more... Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria MONDAY, 24 MARCH 2014 Novartis Novartis Novartis announced that the US Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), an unpredictable and debilitating skin disease that is known as chronic spontaneous urticaria (CSU) outside of the US. In the US, Xolair is indicated for CIU in adults and adolescents (12 years of age and above) who remain symptomatic despite H1-antihistamine treatment[5]. Read more... New therapeutic target discovered for Alzheimer's disease FRIDAY, 21 MARCH 2014 A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-A? peptides linked to Alzheimer's disease (AD). Moreover, the candidate inhibitor drug has been shown to be safe in humans. Read more... Multidisciplinary research team proposes new model for clinical trials THURSDAY, 20 MARCH 2014 Experts across academia, industry and government propose a new method for health care providers to get the right treatments to the right patients at the right time. This new approach, A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials, published in Nature Clinical Pharmacology & Therapeutics, recommends a seamless transition from controlled experiments to real-world comparative effectiveness trials. Read more... Major breakthrough in developing new cancer drugs: Capturing leukemic stem cells WEDNESDAY, 19 MARCH 2014 The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs. Read more... Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development TUESDAY, 18 MARCH 2014 Bayer Bayer With an investment of more than 500 million Euros at its sites in Wuppertal and Leverkusen, Germany, Bayer will establish additional capacities for the manufacturing of the recombinant factor VIII (rFVIII) hemophilia products that are currently in development. The investigational therapy options for hemophilia patients - a plasma protein-free rFVIII (BAY 81-8973) and a long-acting rFVIII (BAY 94-9027) - are both currently in Phase III clinical trials. Read more...

    Continue Reading »

  • Cork Learning Festival 2014

    27 March, 2014

    The 11th Cork Lifelong Learning Festival will take place from Monday April 7 to Sunday April 13, 2014

    Continue Reading »

  • April

  • Biopharma group Alexion to hire 200 at new Dublin plant

    03 April, 2014

    Rare disease specialist Alexion has announced another €75 million investment in Ireland, creating a further 200 jobs.

    Continue Reading »

  • Aspirin can reduce colorectal cancer risks for those with specific gene

    24 April, 2014

    The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene. The extraordinary finding comes from a multi-institutional team that analyzed data and other material from two long-term studies involving nearly 128,000 participants. The researchers found that individuals whose colons have high levels of a specific gene product - 15-hydroxyprostaglandin dehydrogenase (15-PGDH) RNA - dramatically reduce their chances of developing colorectal cancer by taking aspirin. In contrast, the analgesic provides no benefit to individuals whose colons show low levels of 15-PGDH. The findings appear in the April 23 edition of Science Translational Medicine. While previous trials and prospective studies had indicated that aspirin could reduce colorectal cancer risk, this retrospective study provides the first evidence to help explain why aspirin benefits some people, but not others.

    Continue Reading »

  • Pfizer Confirms prior discussions with AstraZeneca

    30 April, 2014

    Pfizer Inc. confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction. After limited high-level discussions, AstraZeneca declined to pursue negotiations. The discussions were discontinued on 14 January 2014 and Pfizer then ceased to consider a possible transaction. In light of recent market developments, Pfizer contacted AstraZeneca on 26 April 2014 seeking to renew discussions in order to develop a proposal that could be recommended by both companies to their shareholders. AstraZeneca again declined to engage. Pfizer is currently considering its options with respect to AstraZeneca.

    Continue Reading »

  • May

  • Clarification regarding Pfizer statement

    21 May, 2014

    AstraZeneca PLC ("AstraZeneca") notes the announcement made by Pfizer Inc. ("Pfizer") dated 19 May 2014 seeking to clarify certain matters set out in its announcement on 18 May 2014 which set out its final proposal to AstraZeneca (the "Final Proposal Announcement"). Following some questions from shareholders, AstraZeneca wishes to make clear the following points:

    Continue Reading »

  • Novartis launches 7-Day Challenge

    28 May, 2014

    Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS

    Continue Reading »

  • June

  • AbbVie’s upgraded facility in Sligo to generate 175 new jobs

    03 June, 2014

    Biopharmaceutical firm says €85m expansion will support development of new pipeline therapies

    Continue Reading »

  • Medical device chief with a healthy outlook on business

    13 June, 2014

    Innovation and adaptation are key strategies for Dublin-based multinational healthcare company Covidien, says its Brazilian CEO, José E Almeida

    Continue Reading »

  • Letters of Credit Operations Training and Electrostatic discharge, training provider required.

    Letters of Credit Operations Training and Electrostatic discharge, training provider required.

    13 June, 2014

    We are looking for a provider to deliver Letters of Credit Operations Training and Electrostatic discharge Training. If you can deliver either of these programmes please contact Susan on 087-2876731.

    Continue Reading »

  • Pharma giant employees begin voting on cuts ‘deal’

    19 June, 2014

    Employees at pharmaceutical giant Bausch + Lomb have begun voting on a cutbacks "deal" which could decide if the plant will remain open into the future.

    Continue Reading »

  • FDA issues guidance to support the responsible development of nanotechnology products

    26 June, 2014

    Three final guidance's and one draft guidance were issued by the U.S. Food and Drug Administration providing greater regulatory clarity for industry on the use of nanotechnology in FDA-regulated products.

    Continue Reading »

  • July

  • Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE antibody blinatumomab in acute lymphoblastic leukemia

    02 July, 2014

    Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow(1).

    Continue Reading »

  • Pfizer to keep 100 workers after review

    Pfizer to keep 100 workers after review

    11 July, 2014

    Pfizer has confirmed that a change in work practices and an upsurge in workload means it is not going to press ahead with 100 of the 130 redundancies it had flagged one of its Cork plants two years ago.

    Continue Reading »

  • Novartis to license Google "smart lens" technology

    16 July, 2014

    Novartis announced that its eye care division Alcon has entered into an agreement with a division of Google Inc. to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals.

    Continue Reading »

  • Merck strengthens commitment to Chinese growth market

    23 July, 2014

    Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, today reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy.

    Continue Reading »

  • Scientists discover new, noncommittal mechanism of drug resistance

    30 July, 2014

    Microorganisms like bacteria and fungi can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs. These permanent mutations were once thought to be the only way for drug-resistant strains to evolve. Now a new study has shown that microorganisms can use a temporary silencing of drug targets - known as epimutations - to gain the benefits of drug resistance without the commitment.

    Continue Reading »

  • August

  • In search for Alzheimer's drug

    08 August, 2014

    Researchers at Yale School of Medicine have discovered a new drug compound that reverses the brain deficits of Alzheimer's disease in an animal model. Their findings are published in the Aug. 5 issue of the journal PLoS Biology. The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory.

    Continue Reading »

  • Bone drugs may not protect osteoporotic women from breast cancer

    13 August, 2014

    Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF). The drugs' protective effect was widely assumed after several observational studies showed that women who took them were less likely to get breast cancer.

    Continue Reading »

  • Aspirin has a second effect

    20 August, 2014

    Hugely popular non-steroidal anti-inflammation drugs like aspirin, naproxen and ibuprofen all work by inhibiting or killing an enzyme called cyclooxygenase - a key catalyst in production of hormone-like lipid compounds called prostaglandins that are linked to a variety of ailments, from headaches and arthritis to menstrual cramps and wound sepsis.

    Continue Reading »

  • September

  • Scientists discover how to 'switch off' autoimmune diseases

    04 September, 2014

    Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue. Rather than the body's immune system destroying its own tissue by mistake, researchers at the University of Bristol have discovered how cells convert from being aggressive to actually protecting against disease.

    Continue Reading »

  • Expo Cork 9th Sept 2014

    08 September, 2014

    Tuesday the 9th of September at the Silver Springs Moran Hotel in Cork from 1pm to 6pm. http://jobsexpo.ie/

    Continue Reading »

  • GSK joins with research councils in UK and South Africa to tackle non-communicable diseases

    11 September, 2014

    GSK has announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases (NCDs) in Africa, as part of GSK's Africa NCD Open Lab initiative.

    Continue Reading »

  • October

  • Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study

    01 October, 2014

    Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab

    Continue Reading »

  • The sterilisation principles

    01 October, 2014

    We are looking for a provider to deliver The sterilisation principles course. If you can deliver this programme could you please contact Cora on 0871245950.

    Continue Reading »

  • Probiotic yogurt could help protect against heavy metal poisoning

    09 October, 2014

    New research shows probiotic yogurt can reduce the uptake of certain heavy metals and environmental toxins by up to 78% in pregnant women. Led by Scientists at Lawson Health Research Institute's Canadian Centre for Human Microbiome and Probiotic Research, this study provides the first clinical evidence that a probiotic yogurt can be used to reduce the deadly health risks associated with mercury and arsenic.

    Continue Reading »

  • Limerick firm sold for $150 million after three years

    16 October, 2014

    A Limerick-based medical technology company founded just three years ago has been sold for about $150 million (€117 million). New York Stock Exchange- listed Becton Dickinson (BD) acquired GenCell Biosystems, founded by 34-year-old Kieran Curran, on Monday.

    Continue Reading »

  • Protecting us from our cells

    23 October, 2014

    Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis. A molecule called insulin-like growth factor-1 (IGF-1) boosts the body's natural defence against this 'friendly fire', scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, have found. The findings, published today in EMBO Molecular Medicine, are especially exciting because IGF-1 is already approved for use in patients, which could speed up the move to clinical trials for treating auto-immune diseases.

    Continue Reading »

  • November

  • Kenny says Bristol-Myers Squibb decision ‘a vote of confidence’

    18 November, 2014

    American pharmaceutical company Bristol-Myers Squibb is to create up to 400 new jobs in Dublin as part of a $900 million (€720 million) investment in a new plant in Blanchardstown. The 30,000-square metre project will house six 15,000-litre bioreactors and a purification area as well as office and laboratory space. The facility will be built on the grounds of the company’s existing pharmaceutical manufacturing plant in Cruiserath, Co Dublin, and is due to be completed by 2019. Taoiseach Enda Kenny described the decision a “really strong vote of confidence for Ireland” particularly after the decision to close the controversial “Double Irish” tax loophole in the budget.

    Continue Reading »

  • Get Your Foot in the Door

    21 November, 2014

    We are delighted to report that our Get your foot in the Door Event in the Silversprings Hotel on the 13th November went extremely well with over 130 people attending both from industry and Jobseekers.

    Continue Reading »

  • Vegetable oil ingredient key to destroying gastric disease bacteria

    26 November, 2014

    Vegetable oil ingredient key to destroying gastric disease bacteria Wednesday, 26 November 2014 E-mailPrintPDF The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils. In mice, LipoLLA was safe and more effective against H. pylori infection than standard antibiotic treatments.

    Continue Reading »

  • December

  • Lyophilisation Training

    02 December, 2014

    We are looking for a provider to deliver a Lyophilisation 2 day programme. If you can deliver this training please contact Susan on 087-2876731.

    Continue Reading »

  • Bristol-Myers Squibb Foundation

    04 December, 2014

    Bristol-Myers Squibb Foundation awards nine grants to support care for high-risk patients with hepatitis B and C in China and India

    Continue Reading »

  • Abbott completes acquisition of Veropharm

    12 December, 2014

    Abbott (NYSE: ABT) today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. Abbott has had a presence in Russia for nearly 40 years and, in line with its long-term commitment to growing global healthcare markets and capabilities, the company is committed to providing a reliable supply of its healthcare products to Russian patients. Through this acquisition, Abbott establishes a manufacturing footprint in Russia through Veropharm's production facilities, which include a new manufacturing facility currently under construction. Abbott also obtains a portfolio of medicines that is well aligned with its current pharmaceutical therapeutic areas of focus in women's health, central nervous system, cardiovascular and gastroenterology, while adding an offering in the field of oncology and pharmaceutical R&D capabilities for Russia. Abbott acquired control of Veropharm for 16.7 billion rubles (or approximately $305 million U.S. dollars) through its purchase of Limited Liability Company Garden Hills, the holding company that currently owns approximately 98 percent of Veropharm. Abbott will fund the transaction with cash on the company's balance sheet. The transaction will not impact ongoing earnings-per-share guidance for 2014.

    Continue Reading »

  • Pharmachem are delighted to congratulate the APICS students.

    16 December, 2014

    Charles Ryan Purcell, Karen Keating. Karine Yuric Buttimer (Tornier) and Garry Benson all completed the certificate in Production and Inventory Management (CPIM). The rest of the group, Peter O’Driscoll, Oonagh Horgan, Elayne Harris, Siobhan Clarke, Diane Harrington, Maeve Pigott are all at different stages of the journey and were delighted at attempting another module on this sometimes frustrating and difficult journey

    Continue Reading »

  • Training for jobseekers

    30 December, 2014

    at Pharmachemskillnet we also provide training for the unemployed. Places are FREE so why not register and take the opportunity to upskill at no cost to you. Click on the link below and watch the video for further information.

    Continue Reading »